S&P 500   2,999.17 (+0.11%)
DOW   26,808.96 (+0.08%)
QQQ   191.81 (-0.02%)
AAPL   242.61 (+1.10%)
FB   184.40 (+1.13%)
MSFT   135.92 (-0.33%)
GOOGL   1,249.91 (+0.70%)
AMZN   1,751.59 (-0.80%)
CGC   21.29 (+0.66%)
NVDA   194.90 (-0.36%)
MU   44.65 (-0.02%)
BABA   169.23 (-0.39%)
GE   9.14 (+0.88%)
AMD   31.53 (+0.03%)
T   37.79 (-1.00%)
BAC   31.34 (+0.45%)
GILD   66.38 (+0.79%)
DIS   130.86 (-1.17%)
S&P 500   2,999.17 (+0.11%)
DOW   26,808.96 (+0.08%)
QQQ   191.81 (-0.02%)
AAPL   242.61 (+1.10%)
FB   184.40 (+1.13%)
MSFT   135.92 (-0.33%)
GOOGL   1,249.91 (+0.70%)
AMZN   1,751.59 (-0.80%)
CGC   21.29 (+0.66%)
NVDA   194.90 (-0.36%)
MU   44.65 (-0.02%)
BABA   169.23 (-0.39%)
GE   9.14 (+0.88%)
AMD   31.53 (+0.03%)
T   37.79 (-1.00%)
BAC   31.34 (+0.45%)
GILD   66.38 (+0.79%)
DIS   130.86 (-1.17%)
Log in

Applied Therapeutics Stock Price, News & Analysis (NASDAQ:APLT)

$15.50
-1.00 (-6.06 %)
(As of 10/23/2019 12:37 PM ET)
Today's Range
$15.00
Now: $15.50
$17.51
50-Day Range
$9.25
MA: $10.57
$16.37
52-Week Range
$7.95
Now: $15.50
$16.75
Volume1,931 shs
Average Volume19,148 shs
Market Capitalization$264.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLT
CUSIPN/A
CIKN/A
Phone212-220-9226

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees4
Market Cap$264.28 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.


Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics (NASDAQ:APLT) released its earnings results on Monday, August, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.12. View Applied Therapeutics' Earnings History.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Applied Therapeutics.

What price target have analysts set for APLT?

4 analysts have issued 12 month price targets for Applied Therapeutics' stock. Their forecasts range from $24.00 to $29.00. On average, they anticipate Applied Therapeutics' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 71.0% from the stock's current price. View Analyst Price Targets for Applied Therapeutics.

What is the consensus analysts' recommendation for Applied Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Therapeutics.

Has Applied Therapeutics been receiving favorable news coverage?

News stories about APLT stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Applied Therapeutics earned a news sentiment score of 0.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Applied Therapeutics.

Are investors shorting Applied Therapeutics?

Applied Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 60,800 shares, an increase of 406.7% from the August 30th total of 12,000 shares. Based on an average daily volume of 16,200 shares, the short-interest ratio is presently 3.8 days. Currently, 0.8% of the shares of the stock are sold short. View Applied Therapeutics' Current Options Chain.

Who are some of Applied Therapeutics' key competitors?

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Allena Pharmaceuticals (ALNA), ADMA Biologics (ADMA), Iovance Biotherapeutics (IOVA), Aeglea Bio Therapeutics (AGLE), Aqua Metals (AQMS), Cronos Group (CRON), eHealth (EHTH), Evolus (EOLS), Fate Therapeutics (FATE) and Amicus Therapeutics (FOLD).

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the folowing people:
  • Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 40)
  • Dr. Mark Joseph Vignola, Chief Financial Officer (Age 42)
  • Dr. Riccardo Perfetti, Chief Medical Officer (Age 59)

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

When does Applied Therapeutics' lock-up period expire?

Applied Therapeutics' lock-up period expires on Monday, November 11th. Applied Therapeutics had issued 4,000,000 shares in its IPO on May 14th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. After the expiration of Applied Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $15.50.

How big of a company is Applied Therapeutics?

Applied Therapeutics has a market capitalization of $264.28 million. Applied Therapeutics employs 4 workers across the globe.View Additional Information About Applied Therapeutics.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is http://www.appliedtherapeutics.com/.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]


MarketBeat Community Rating for Applied Therapeutics (NASDAQ APLT)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  49
MarketBeat's community ratings are surveys of what our community members think about Applied Therapeutics and other stocks. Vote "Outperform" if you believe APLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel